ITA4900
ITA4900
ITA4900
from
$526.00
Price in reward points: 526
- Catalog: ITA4900
- Gene/Protein: MYLIP
- Product Description: Immunotag™ MYLIP Antibody
Available Options
-
Description
Immunotag™ MYLIP Antibody
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein MYLIP Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC,IF/ICC,ELISA Recommended Dilution WB 1:500~1:1000 IHC: 1:50~1:200, IF/ICC 1:100-1:500 Concentration 1 mg/ml Reactive Species Human,Mouse,Rat Host Species Rabbit Immunogen A synthesized peptide Specificity MYLIP Antibody detects endogenous levels of total MYLIP Purification The antiserum was purified by peptide affinity chromatography. Form Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt Gene Name MYLIP Accession No. Q8WY64 Alternate Names BM-023; BZF1; E3 ubiquitin protein ligase MYLIP; E3 ubiquitin-protein ligase MYLIP; Idol; Inducible degrader of the LDL-receptor; Lipoprotein receptor; MIR; MYLIP; MYLIP_HUMAN; Myosin regulatory light chain interacting protein; PP5242; Description E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. Cell Pathway/ Category Primary Polyclonal Antibody Protein MW 50 KD Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet |
|
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | MYLIP |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500~1:1000 IHC: 1:50~1:200, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse,Rat |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide |
| Specificity | MYLIP Antibody detects endogenous levels of total MYLIP |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | MYLIP |
| Accession No. | Q8WY64 |
| Alternate Names | BM-023; BZF1; E3 ubiquitin protein ligase MYLIP; E3 ubiquitin-protein ligase MYLIP; Idol; Inducible degrader of the LDL-receptor; Lipoprotein receptor; MIR; MYLIP; MYLIP_HUMAN; Myosin regulatory light chain interacting protein; PP5242; |
| Description | E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Activity depends on E2 enzymes of the UBE2D family. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 50 KD |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |